New secondary metabolites with cytotoxicity from fungus Penicillium roqueforti
Tóm tắt
Two novel compounds including a cyclohelminthol type polyketide (namely oxaleimide K, 1) and a maleimide derivative (namely peniroquefortine A, 2), and a new natural product (namely 2-(acetylamino)-N-[(1E)-2-phenylethenyl]-acetamide, 3), together with four known compounds (4–7), were isolated and identified from fungus Penicillium roqueforti, which was separated from the root soil of Hypericum beanii N. Robson collected from the Shennongjia Forestry District, Hubei Province. Their structures including absolute configurations were mainly established by the NMR spectroscopy analyses and single-crystal X-ray diffraction experiment. Compound 1 represents the second example of a cyclohelminthol type polyketide, which features a rare 6/6/5/5 tetracyclic system and a branched aliphatic chain containing a terminal olefin (oct-1-en-3-yl) moiety, and compound 2 possesses an unprecedented carbon skeleton that is uniquely defined by a maleimide moiety linked to the respective 4-methylene-2-(3-methylbut-2-en-1-yl)-phenol and para-substituted aromatic moieties via the carbon-carbon bonds. Remarkably, the absolute configuration of a cyclohelminthol type polyketide as exemplified by compound 1 is determined by the single-crystal diffraction analysis for the first time, highlighting an E-configuration for the linkage of a succinimide moiety and a tetrahydrofuran moiety for 1 rather than a Z-configuration as previously reported in the biosynthesis study, which gives a new insight into the structural elucidation of this category of polyketides. Additionally, compound 1 exhibited significant cytotoxic activity against multiple tumor cells, especially against the Farage and SU-DHL-2 cells (IC50 < 20 µM, 48 h). Further mechanism study revealed that compound 1 significantly induced cell cycle arrest in Farage and SU-DHL-2 cells by causing abnormal ROS level and triggering oxidative stress.
Tài liệu tham khảo
Chan SH, Chui CH, Chan SW, Kok SHL, Chan D, Tsoi MYT, Leung PHM, Lam AKY, Chan ASC, Lam KH, Tang JCO. Synthesis of 8-hydroxyquinoline derivatives as novel antitumor agents. ACS Med Chem Lett. 2013;4:170–4.
Guo C, Dong E, Lai Q, Zhou S, Zhang G, Wu M, Yue X, Tao Y, Peng Y, Ali JM, Lu Y, Fu Y, Lai W, Zhang Z, Ma F, Yao Y, Gou L, Yang H, Yang J. Effective antitumor activity of 5T4-specific CAR-T cells against ovarian cancer cells in vitro and xenotransplanted tumors in vivo. MedComm. 2020;1:338–50.
Shi R, Tang Y, Miao H. Metabolism in tumor microenvironment: implications for cancer immunotherapy. MedComm. 2020;1:47–68.
Pich O, Bailey C, Watkins TBK, Zaccaria S, Jamal-Hanjani M, Swanton C. The translational challenges of precision oncology. Cancer Cell. 2022;40:458–78.
Chen S, Zhen Y. Research progress in new anti-tumor drugs on different targets derived from microorganisms. Acta Pharm Sin. 2018;53:833–8.
Duan Y, Meng L. Research progress in multi-targeted anti-tumor natural products. Acta Pharm Sin. 2021;56:403–13.
Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83:770–803.
Xu J, Meng L, Qing C. The clinical application and development of traditional antitumor drug. Acta Pharm Sin. 2021;56:1551–61.
Wu Q, Qian W, Sun X, Jiang S. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J Hematol Oncol. 2022;15:143–3.
Zhao S, Wang D, Zhao H, Gong J, Zhang J, Fang W, Ma F, Xu B, Li J, Hu X, Ba Y, Chen X, Yang Z, Shen L, Jiang J, Zhang L. Time to raise the bar: transition rate of phase 1 programs on anticancer drugs. Cancer Cell. 2022;40:233–5.
Moreau S, Cacan M, Lablache-Combier A, Eremofortin C. A new metabolite obtained from Penicillium roqueforti cultures and from biotransformation of PR toxin. J Org Chem. 1977;42:2632–4.
Omura S, Inokoshi J, Uchida R, Shiomi K, Masuma R, Kawakubo T, Tanaka H, Iwai Y, Kosemura S, Yamamura S. Andrastins A–C, new protein farnesyltransferase inhibitors produced by Penicillium sp. FO-3929. I. producing strain, fermentation, isolation, and biological activities. J Antibiot. 1996;49:414–7.
Wang J, Yu J, Shu Y, Shi Y, Luo P, Cai L, Ding Z. Peniroquesines A–C: sesterterpenoids possessing a 5-6-5-6-5-fused pentacyclic ring system from Penicillium roqueforti YJ-14. Org Lett. 2018;20:5853–6.
Inose K, Tanaka S, Tanaka K, Hashimoto M. Cyclohelminthol CPs: scope and limitations of density functional theory-based structural elucidation of natural products. J Org Chem. 2021;86:1501–15.
Stewart SG, Ho LA, Polomska ME, Percival AT, Yeoh GCT. Rapid evaluation of Antrodia camphorata natural products and derivatives in tumourigenic liver progenitor cells with a novel cell proliferation assay. ChemMedChem. 2009;4:1657–67.
Gooßen LJ, Blanchot M, Salih KSM, Gooßen K. Ruthenium-catalyzed addition of primary amides to alkynes: a stereoselective synthesis of secondary enamides. Synthesis. 2009;13:2283–8.
Talontsi FM, Facey P, Tatong MDK, Islam MT, Frauendorf H, Draeger S, Tiedemann VA, Laatsch H. Zoosporicidal metabolites from an endophytic fungus Cryptosporiopsis sp. of Zanthoxylum leprieurii. Phytochemistry. 2012;83:87–94.
Yoshida Y, Haraguchi D, Ukuda-Hosokawa R, Andou T, Matsuyama T, Kohama T, Eguchi T, Ohno S, Ono H, Nishida R. Synthesis and activity of 3-oxo-α-ionone analogs as male attractants for the solanaceous fruit fly, Bactrocera latifrons (Diptera: Tephritidae). Biosci Biotechnol Biochem. 2021;85:2360–7.
Zhao Y, Liu D, Proksch P, Yua S, Lin W. Isocoumarin derivatives from the sponge-associated fungus Peyronellaea glomerata with antioxidant activities. Chem Biodivers. 2016;13:1186–93.
Chen L, Zhu T, Zhu G, Liu Y, Wang C, Pawinee P, Arthit C, Zhu W. Bioactive natural products from the marine-derived Penicillium brevicompactum OUCMDZ-4920. Chin J Org Chem. 2017;37:2752–62.
Vurusaner B, Poli G, Basaga H. Tumor suppressor genes and ROS: complex networks of interactions. Free Radical Bio Med. 2012;52:7–18.
Zhu C, Shi H, Wu M, Wei X, Lin W. A dual MET/AXL small-molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironment. MedComm. 2020;1:103–18.